The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Eric Smith, Andrew Aguirre, Sam Klempner granted additional $300,000 from DeGregorio Family Foundation to study immunotherapy in gastroesophageal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Eric Smith

Andrew Aguirre

Sam Klempner

The DeGregorio Family Foundation, with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative, or GEMINI, awarded $300,000 to Eric Smith and Andrew Aguirre, both of Dana-Farber Cancer Institute, and Sam Klempner, of Massachusetts General Hospital, to reward the progress they have made on their grant in a little over a year. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account